Bulaquine Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Bulaquine is a derivative of primaquine that was introduced in India in combination with chloroquine as a treatment against malaria. The compound is prepared by condensation of primaquine with 3-acetyl-y-butyrolactone in presence of a catalytic amount of base. Bulaquine kills the latent tissue stage (hypnozoites) of the parasite Plasmodium vivax accumulated in the liver and responsible for relapses. Its efficient anti-relapse activity was demonstrated against sporozoite induced Plasmodium cynomolgi infection in rhesus monkey. Bulaquine is safer than primaquine, the preceding candidate against malaria relapse. Although it is stable at pH 7-8, bulaquine is hydrolyzed to primaquine under acidic conditions.

Originator

CDRI (India)

Trademarks

Aablaquin

Bulaquine Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Bulaquine Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
TargetMol Chemicals Inc.	+1-781-999-5354;	support@targetmol.com	United States	39037	58
TargetMol Chemicals Inc.	+17819995354	marketing@targetmol.com	United States	19956	58
Tianjin Kailiqi Biotechnology Co., Ltd.	15076683720	klq@cw-bio.com	China	9689	55
TargetMol Chemicals Inc.	15002134094	marketing@targetmol.cn	China	29867	58

79781-00-3()Verwandte Suche:

---

• compound 80-53
• 1-[4,5-Dihydro-2-[[4-[(6-methoxyquinoline-8-yl)amino]pentyl]amino]furan-3-yl]ethanone
• CDRI-80/53
• N-[(3-Acetyl-4,5-dihydrofuran)-2-yl]-N'-(6-methoxy-8-quinolinyl)-1,4-pentanediamine
• Bulaquine
• 2(3H)-Furanone, dihydro-3-[1-[[4-[(6-methoxy-8-quinolinyl)amino]pentyl]amino]ethylidene]-
• aablaquine
• 79781-00-3